Abstract: An effective anti-nematode methodology entails contacting nematodes with a biologically effective amount of at least one compound according to formula I: where Q, Q?, R1, R2, and n are defined herein, or with a stereoisomer, solvate, or pharmaceutically acceptable salt of such compound.

Abstract: A system and method of processing seismic data obtained using a plurality of towed single-component receivers in a marine environment is described, the towed single-component receivers configured to measure compressional P waves. The method comprises retrieving seismic data from a storage device, the seismic data comprising P-P data and shear mode data, wherein the P-P data and shear mode data were both received at the towed single-component receivers configured to measure compressional P waves to generate the seismic data. The method further comprises processing the seismic data to extract SV-P shear mode data and generating shear mode image data based on the extracted shear mode data.

Abstract: There are provided, inter alia, lipophilic monophosphorylated derivatives of gemcitabine. There are further provided nanoparticles compositions incorporating lipophilic monophosphorylated derivatives of gemcitabine, pharmaceutical compositions thereof, and a method of treating cancer or a viral infection in a subject in need thereof, which method includes administration of a pharmaceutical composition disclosed herein.

Abstract: Provided herein are methods and compositions inter alia for treating diseases, including hyperproliferative diseases, migraine headaches, and depression.

Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.

Abstract: Disclosed is a functional NIRS imaging system including an elastomeric cap, a set of transmit optical fibers and a set of receive optical fibers terminating on the inside surface of the elastomeric cap. A pair of light sources combines to produce a collimated light beam at two wavelengths. An optical modulation system, converts the light beam into a plurality of probe light beams, modulates the plurality of probe light beams and directs each probe light beam into a transmit fiber. An optical detection system accepts scattered photons from subcutaneous tissue underneath the elastomeric cap as a plurality of collected light beams and converts them into a time series of electronic images, stores the electronic images into the memory and processes the electronic images using. The system displays the resulting image on a display as a hemoglobin oxygen saturation map.

Abstract: The invention relates to a transportable therapeutic cartridge, a therapeutic agent robotic mixer and a method for providing therapeutic infusion services. The transportable therapeutic cartridge is configured to be used to manually mix therapeutic agents or to be coupled to a therapeutic agent robotic mixer, such that the robotic mixer can access therapeutic agents disposed in the cartridge. The cartridge, mixer, and method provide therapeutic infusions in a just-in-time fashion, so as to minimize risk to patients and facility staff while maximizing the use and safety of the therapeutics.

Abstract: The present invention includes methods and compositions related to diagnosis of bladder cancer, including the presence of bladder cancer and/or the type or stage of bladder cancer. In specific embodiments, the expression of one, two, three, four, five, or more miRNAs of the invention are associated with detection of bladder cancer, typing of bladder cancer, or staging of bladder cancer. Kits and microarrays are encompassed in the invention.

Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.